CM
RVNC

Cigogne Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Cigogne Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$340K Buy
+111,825
New +$487K 0.2% 74

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Cigogne Management's RVNC Position: Q4 2024 in Review

Cigogne Management opened a new position in Revance Therapeutics, Inc. (RVNC) in Q4 2024: 111,825 shares worth $340K. The stake represents 0.2% of the portfolio and ranks #74 among its holdings.

173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Cigogne Management held 111,825 shares of Revance Therapeutics, Inc. worth $340K as of Q4 2024.
  • Revance Therapeutics, Inc. was a new Cigogne Management position in Q4 2024.
  • Revance Therapeutics, Inc. made up 0.2% of Cigogne Management's portfolio in Q4 2024, its #74 holding.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Cigogne Management's 13F filing for Q4 2024, filed 14 Feb 2025.